Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
Cantargia AB (publ), a biotechnology company, engages in the research and development of antibody-based treatments for life threatening diseases. The company is developing CAN04, an antibody against Interleukin-1 Receptor Accessory Protein (IL1RAP) to recognize cancer cells and stimulate natural immune system to destroy such cells, as well as block the tumor inflammation that is driven...
Company Valuation
From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. In particular, the stock is underpriced on P/E, 'cheap' on
Target Price
The average target price of CANTA.ST is 9.8 and suggests 68% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell